期刊文献+

草酸铂联合卡培他滨治疗晚期大肠癌临床观察 被引量:1

The clinical observation of oxaliplatin combined with capecitabin for patients with advanced colorectal cancer
全文增补中
导出
摘要 目的观察草酸铂(Oxaliplatin)联合卡培他滨(商品名:希罗达)治疗晚期大肠癌的近期疗效及患者不良反应。方法采用草酸铂130mg/m^2,静脉滴注2 h,第1天,希罗达2000mg·m^(-2)·d^(-1),分2次口服,第1天至第14天,联合治疗晚期大肠癌患者42例,21 d为1个周期,至少连用3个周期。结果全组中完全缓解2例、部分缓解15例,有效率40.5%(17/42)。治疗后Karnofsky评分提高24例(57.1%)。患者主要不良反应为脱发、外周感觉神经异常、消化道反应、骨髓抑制,均可以耐受。结论草酸铂联合卡培他滨方案治疗晚期大肠癌具有较好的疗效,患者不良反应可以耐受,值得深入研究。 Objective To observe the therapeutic effect and toxicity reaction of Oxaliplatin com- bined with XeLoda in the treatment of 42 patients with advanced colorectal cancer.Methods All the pa- tients were treated with Oxaliplatin(130 mg/m^2,ivgtt for 2 h,d1)combined with XeLoda(2000 mg·m^(-2)·d^(-1), po,bid,d1 to d14).The regime was repeated every 21 days for at least 3 consecutive cycles.Results The to- tal response rate was 40.5%(17/42)in which 2 got CR and 15 PR.24 patients got Kamofsky score increased. The major toxic effects were alopecia,peripheral neuritis,gastrointestinal tract reactions and myelosuppression. Conclusion Oxaliplatin combined with XeLoda regimen is effective in the treatment of advanced colorectal cancer,and its toxicity is tolerable.It is worth studying in the future.
出处 《肿瘤研究与临床》 CAS 2007年第6期391-392,共2页 Cancer Research and Clinic
关键词 结直肠肿瘤 草酸铂 卡培他滨 药物疗法 联合 Colorectal neoplasms Oxaliplatin Capecitabine Drug therapy,combination
  • 相关文献

参考文献8

  • 1阮新建,刘端祺,李小梅,李红英,苏才贵.卡培他滨二线治疗32例晚期肿瘤的效果观察[J].华北国防医药,2006,18(1):63-64. 被引量:5
  • 2林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床,2000,27(11):872-874. 被引量:333
  • 3孙燕,周际昌.临床肿瘤内科手册[M]人民卫生出版社,1996.
  • 4Miwa M,,UraM,Nishida M,et al.Design of a novel oral fluoropyrimi- dine carbamate,capecitabine,which generates 5-fluorouracil selec- tively in tumors by enzymes concentrated in human liver and cancer tissue. European Journal of Cancer . 1998
  • 5Reigner B,Blesch K,Weidekamm E.Clinical pharmacokinetics of capecitabine. Clinical Pharmacokinetics . 2001
  • 6Courdier I,Grabbe L,Andreau K,et al.Oxaliplatin-induced mito- chondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncegene . 2004
  • 7Scheithauer W,Kornek GV,Raderer M,et al.Intermittent weekly high-dose capecitabine in combination with oxaliplatin:a phaseⅠ/Ⅱstudy in first-line treatment of patients with advanced colorectal can- cer. Annals of Oncology . 2002
  • 8Scheithauer W,Kornek GV,Raderer M,et al.Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first - line treatment in advanced colorectal cancer. Journal of Clinical Oncology . 2003

二级参考文献8

  • 1Li X M,Arch Toxicol,1998年,72卷,9期,574页
  • 2赵龙妹.实体瘤的疗效评价标准[A].见:孙燕,周际昌,主编.临床肿瘤内科手册[M].第4版.北京:人民卫生出社,2003.106-111.
  • 3孙燕.抗肿瘤药物的近期和远期不良反应[A].见:孙燕,周际昌,主编.临床肿瘤内科手册[M].第4版.北京:人民卫生出社,2003.97-105.
  • 4Reigner B,Blesch K,Weidekamm E.Clinical pharmacokinetics of capecitabine[ J ].Clin Pharmacokinet,2001,40:85-104.
  • 5Koizumi W,Saigenji K,Ujiie S,et al.A pilot phase Ⅱ study of capecitabine in advanced or recurrent gastric cancer[J].Oncology,2003,64:232-236.
  • 6Walko CM,Lindley C.Capecitabine:a review[J].Clin Ther,2005,27:23-44.
  • 7Marse H,van-Cutsem E,Grothey A,et al.Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda)[J].Eur J Oncol Nurs,2004,8:16-30.
  • 8孙燕,管忠震,金懋林,李维廉,李丽庆,石廷章,周立中,隋广杰,许立功,宋恕平,许德凤,李容,李扬,黄富麟,张嘉庆,张和平,鞠利雅.奥沙利铂单药或与氟尿嘧啶-甲酰四氢叶酸联合应用治疗晚期大肠癌Ⅱ期临床试用报告[J].癌症,1999,18(3):237-240. 被引量:344

共引文献336

同被引文献2

引证文献1

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部